For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
35
views
79
references
 Top references
cited by
105
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      201
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics

      review-article
      Author(s): ,
      Publication date (Electronic):
      Journal: Journal of Pharmaceutical Investigation
      Publisher: Springer Singapore
      Keywords: Nanomedicines, Pharmacokinetics, Delivery, Guidelines

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nanomedicines have evolved into various forms including dendrimers, nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles since their first launch in the market. Widely highlighted benefits of nanomedicines over conventional medicines include superior efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profiles of pharmaceutical ingredients. Especially, various kinetic characteristics of nanomedicines in body are further influenced by their formulations. This review provides an updated understanding of nanomedicines with respect to delivery and pharmacokinetics. It describes the process and advantages of the nanomedicines approved by FDA and EMA. New FDA and EMA guidelines will also be discussed. Based on the analysis of recent guidelines and approved nanomedicines, key issues in the future development of nanomedicines will be addressed.

          Related collections

          Most cited references79

          • Record: found
          • Abstract: found
          • Article: not found

          Nanoparticles in medicine: therapeutic applications and developments.

          L. Zhang, F. Gu, J M Chan … (2008)
          Nanotechnology is the understanding and control of matter generally in the 1-100 nm dimension range. The application of nanotechnology to medicine, known as nanomedicine, concerns the use of precisely engineered materials at this length scale to develop novel therapeutic and diagnostic modalities. Nanomaterials have unique physicochemical properties, such as ultra small size, large surface area to mass ratio, and high reactivity, which are different from bulk materials of the same composition. These properties can be used to overcome some of the limitations found in traditional therapeutic and diagnostic agents.
          Article 0 comments Cited 500 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

            Neil Desai, Vuong Trieu, Zhiwen Yao … (2006)
            ABI-007, an albumin-bound, 130-nm particle form of paclitaxel, was developed to avoid Cremophor/ethanol-associated toxicities in Cremophor-based paclitaxel (Taxol) and to exploit albumin receptor-mediated endothelial transport. We studied the antitumor activity, intratumoral paclitaxel accumulation, and endothelial transport for ABI-007 and Cremophor-based paclitaxel. Antitumor activity and mortality were assessed in nude mice bearing human tumor xenografts [lung (H522), breast (MX-1), ovarian (SK-OV-3), prostate (PC-3), and colon (HT29)] treated with ABI-007 or Cremophor-based paclitaxel. Intratumoral paclitaxel concentrations (MX-1-tumored mice) were compared for radiolabeled ABI-007 and Cremophor-based paclitaxel. In vitro endothelial transcytosis and Cremophor inhibition of paclitaxel binding to cells and albumin was compared for ABI-007 and Cremophor-based paclitaxel. Both ABI-007 and Cremophor-based paclitaxel caused tumor regression and prolonged survival; the order of sensitivity was lung > breast congruent with ovary > prostate > colon. The LD(50) and maximum tolerated dose for ABI-007 and Cremophor-based paclitaxel were 47 and 30 mg/kg/d and 30 and 13.4 mg/kg/d, respectively. At equitoxic dose, the ABI-007-treated groups showed more complete regressions, longer time to recurrence, longer doubling time, and prolonged survival. At equal dose, tumor paclitaxel area under the curve was 33% higher for ABI-007 versus Cremophor-based paclitaxel, indicating more effective intratumoral accumulation of ABI-007. Endothelial binding and transcytosis of paclitaxel were markedly higher for ABI-007 versus Cremophor-based paclitaxel, and this difference was abrogated by a known inhibitor of endothelial gp60 receptor/caveolar transport. In addition, Cremophor was found to inhibit binding of paclitaxel to endothelial cells and albumin. Enhanced endothelial cell binding and transcytosis for ABI-007 and inhibition by Cremophor in Cremophor-based paclitaxel may account in part for the greater efficacy and intratumor delivery of ABI-007.
            Article 0 comments Cited 272 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Microemulsion-based media as novel drug delivery systems.

              M.Jayne Lawrence, Gareth Rees (2000)
              Microemulsions are clear, stable, isotropic mixtures of oil, water and surfactant, frequently in combination with a cosurfactant. These systems are currently of interest to the pharmaceutical scientist because of their considerable potential to act as drug delivery vehicles by incorporating a wide range of drug molecules. In order to appreciate the potential of microemulsions as delivery vehicles, this review gives an overview of the formation and phase behaviour and characterization of microemulsions. The use of microemulsions and closely related microemulsion-based systems as drug delivery vehicles is reviewed, with particular emphasis being placed on recent developments and future directions.
              Article 0 comments Cited 237 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Young Hee Choi:
                ORCID: http://orcid.org/0000-0002-9360-6436
                choiyh@dongguk.edu
                Journal
                Journal ID (nlm-ta): J Pharm Investig
                Journal ID (iso-abbrev): J Pharm Investig
                Title: Journal of Pharmaceutical Investigation
                Publisher: Springer Singapore (Singapore )
                ISSN (Print): 2093-5552
                ISSN (Electronic): 2093-6214
                Publication date (Electronic): 28 November 2017
                Publication date PMC-release: 28 November 2017
                Publication date (Print): 2018
                Volume: 48
                Issue: 1
                Pages: 43-60
                Affiliations
                ISNI 0000 0001 0671 5021, GRID grid.255168.d, College of Pharmacy and Integrated Research Institute for Drug Development, , Dongguk University-Seoul, ; 32 Dongguk-lo, Ilsandong-gu, Goyang, Gyonggi-do 10326 Republic of Korea
                Author information
                http://orcid.org/0000-0002-9360-6436
                Article
                Publisher ID: 370
                DOI: 10.1007/s40005-017-0370-4
                PMC ID: 6244736
                PubMed ID: 30546919
                SO-VID: 8255cf1a-833b-4bfb-9aae-14843ce43a76
                Copyright © © The Author(s) 2017, corrected publication November 2018
                License:

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

                History
                Date received : 12 October 2017
                Date accepted : 8 November 2017
                Funding
                Funded by: This research was supported by a Grant (16173MFDS542) from Ministry of Food and Drug Safety in 2016.
                Categories
                Subject: Review
                Custom metadata
                issue-copyright-statement © The Korean Society of Pharmaceutical Sciences and Technology 2018

                Keywords: nanomedicines,pharmacokinetics,delivery,guidelines
                Data availability:
                Keywords: nanomedicines, pharmacokinetics, delivery, guidelines

                Comments

                Comment on this article

                scite_

                Similar content201

                See all similar

                Cited by105

                See all cited by

                Most referenced authors1,410

                See all reference authors